Corcept Therapeutics Incorporated (CORT)

Operating return on assets (Operating ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	136,952	143,359	127,938	121,929	107,282	98,112	98,869	100,718	112,634	126,799	131,097	131,608	124,477	118,323	106,810	110,129	128,202	132,708	140,993	130,364
Total assets	US$ in thousands	840,553	784,257	714,555	655,935	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494
Operating ROA		16.29%	18.28%	17.90%	18.59%	17.26%	16.52%	18.85%	16.30%	19.31%	23.78%	26.41%	28.11%	29.37%	20.21%	18.79%	19.94%	22.42%	24.85%	28.32%	29.26%

December 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $136,952K ÷ $840,553K
= 16.29%

The operating return on assets (operating ROA) of Corcept Therapeutics Incorporated has shown a gradual decline over the periods from March 31, 2020, to December 31, 2024. Starting at a relatively high level of 29.26% in March 2020, the operating ROA decreased to 16.29% by December 2024.

The declining trend in operating ROA indicates that the company's ability to generate operating profit from its assets has been decreasing over time. This could be a result of various factors such as increasing operating expenses, lower revenue generation, or inefficiencies in asset utilization.

It is essential for Corcept Therapeutics to closely monitor and address the factors contributing to the decline in operating ROA to improve profitability and operational efficiency. This analysis underscores the importance of effective cost management, revenue growth strategies, and optimizing asset utilization to enhance the company's financial performance in the future.